London: Zealand Pharma said on Thursday an early-stage study showed a high dose of its drug helped reduce weight by an average 8.6 per cent after 16 weekly doses.
The company said the data paves the way for testing the drug, petrelintide, in a mid-stage trial for weight loss, which it expects to start later this year.
The weight loss achieved with the high dose of the drug was much higher than the 1.7 per cent reduction with a placebo in one part of the trial that involved 48 participants. Another part of the early-stage study was testing the drug in 20 people with lower doses.
Petrelintide belongs to a class of drugs known as the long-acting amylin analog, which mimics a hormone called amylin that is co-secreted with insulin in response to ingested nutrients.
The Danish company is also working with German drugmaker Boehringer Ingelheim to test another drug survodutide, which belongs to the same class of GLP-1 agonists as Eli Lilly’s Mounjaro and Zepbound and Novo Nordisk’s Ozempic and Wegovy.
(Reporting by Leroy Leo in Bengaluru; Editing by Shilpi Majumdar)
weight loss drug, Health News, Zealand Pharma, drug, petrelintide, early-stage study, high dose, reduce weight
#Zealand #Pharmas #drug #reduces #weight #earlystage #study #HealthWorld
